Purchase this article with an account.
K. Shiramizu, R. Hamilton, J.I. Lim; Regression of Choroidal Metastasis to Taxane Based Chemotherapy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5411.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
PURPOSE: To describe a series of cases of regression of choroidal metastasis after taxane based chemotherapy. DESIGN: Observational case series. METHODS: Patient 1 with a history of adenocarcinoma of the lung presented with photopsias in the left eye. Examination revealed a choroidal mass consistent with metastasis with a maximum height of 1.90 mm. Patient 2 presented with decreased vision in the right eye. The patient had a history of choroidal metastasis from breast cancer in the left eye. This had been treated with a chemotherapy regimen including paclitaxel which resulted in complete regression of the choroidal metastasis. At presentation, examination of the right eye revealed a choroidal mass consistent with a metastasis with a maximum height of 1.30 mm with shallow serous retinal detachment. Results: Patient 1: After starting chemotherapy with docetaxel, symptoms resolved at the 5 month follow–up examination. The maximum height had regressed to 0.96 mm with resolution of subretinal fluid. Patient 2: After starting chemotherapy with docetaxel, the tumor demonstrated regression to 1.16 mm and 0.80 mm at 3 and 6 months, respectively. Conclusions: Systemic taxane based chemotherapy may be a useful treatment for eyes with choroidal metastasis secondary to lung cancer or breast cancer prior to consideration of external beam radiation.
This PDF is available to Subscribers Only